UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-----------------
SCHEDULE 13D
(Rule 13d-101)
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 2)*
Life Medical Sciences, Inc.
- --------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, par value $.001 per share
- --------------------------------------------------------------------------------
(Title of Class of Securities)
53215M 10 1
- --------------------------------------------------------------------------------
(CUSIP Number)
Herbert Moskowitz, 616 Washington Court, Guilderland, New York 12084
(518) 456-1876, with a copy to Irwin M. Rosenthal, Esq.,
Rubin Baum Levin Constant & Friedman, 30 Rockefeller Plaza, New York, NY 10112
- --------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
November 29, 1996
- --------------------------------------------------------------------------------
(Date of Event which Requires Filing of This Statement)
If the filing person has previously filed a statement on Schedule 13G to
report the acquisition which is the subject of this Schedule 13D, and is filing
this schedule because of Rule 13d-1(b)(3) or (4), check the following box |_|.
Note: Six copies of this statement, including all exhibits, should be filed
with the Commission. See Rule 13d-1(a) for other parties to whom copies are to
be sent.
- ----------
* The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities,
and for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be
deemed to be filed for the purpose of Section 18 of the Securities Exchange
Act of 1934 (Act) or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
<PAGE>
SCHEDULE 13D
CUSIP No. 53215M 10 1
- --------------------------------------------------------------------------------
1 Name of Reporting Person
S.S. or I.R.S. Identification No. of Above Person
Herbert Moskowitz
- --------------------------------------------------------------------------------
2 Check the Appropriate Box If a Member of a Group* a. |_|
b. |X|
- --------------------------------------------------------------------------------
3 SEC Use Only
- --------------------------------------------------------------------------------
4 Source of Funds*
N/A
- --------------------------------------------------------------------------------
5 Check Box If Disclosure of Legal Proceedings Is Required Pursuant to Item
2(d) or 2(e) |_|
- --------------------------------------------------------------------------------
6 Citizenship or Place of Organization
United States of America
- --------------------------------------------------------------------------------
7 Sole Voting Power
Number of
Shares 520,127(1)
Beneficially --------------------------------------------------------
Owned By 8 Shared Voting Power
Each
Reporting 677,500(2)
Person --------------------------------------------------------
With 9 Sole Dispositive Power
520,127(1)
--------------------------------------------------------
10 Shared Dispositive Power
677,500(2)
- --------------------------------------------------------------------------------
11 Aggregate Amount Beneficially Owned by Each Reporting Person
1,197,627
- --------------------------------------------------------------------------------
12 Check Box If the Aggregate Amount in Row (11) Excludes Certain Shares* |_|
- --------------------------------------------------------------------------------
13 Percent of Class Represented By Amount in Row (11)
14.58(3)
- --------------------------------------------------------------------------------
14 Type of Reporting Person*
IN
- --------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
(1) Includes shares of Common Stock issuable upon exercise of 49,110 Class A
Warrants and 49,110 Class B Warrants, and 49,110 Class B Warrants issuable
upon exercise of the Class A Warrants which may be exercised at any time
up to September 22, 1997 into 147,330 shares of Common Stock. Also
includes 150,000 shares of Common Stock issuable upon exercise of an
option which is currently exercisable.
(2) Represents 677,500 shares of Common Stock held of record by Magar Inc., of
which Mr. Moskowitz is an officer, director and principal stockholder. Mr.
Moskowitz may be considered to beneficially own, and to have shared
investment and voting power with respect to, all shares of Common Stock
owned by Magar Inc.
(3) Based on 7,914,820 shares of Common Stock outstanding on the date hereof.
INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7
(INCLUDING EXHIBITS) OF THE SCHEDULE AND THE SIGNATURE ATTESTATION.
<PAGE>
Page 3 of 5 pages
This Amendment No. 2 to the statement on Schedule 13D (as defined
below) supplements the statement on Schedule 13D relating to the event date of
February 23, 1995 and Amendment No. 1 thereto filed on March 21, 1995 (the
"Schedule 13D") by Herbert Moskowitz (the "Reporting Person"), relating to the
common stock, $.001 par value per share (the "Common Stock") of Life Medical
Sciences, Inc. (the "Company"). The previous statements filed on both February
23, 1995 on March 21, 1995 are attached hereto as exhibits.
Item 1. Security and Issuer.
Item 1 of the Schedule 13D is hereby supplemented as follows:
This statement relates to the Common Stock, par value $.001 per
share (the "Common Stock") of Life Medical Sciences, a Delaware corporation (the
"Company"). The address of the Company's principal executive office is 379
Thornall Street, Edison, New Jersey, 08837.
Item 5. Interest in Securities of the Issuer.
Item 5(a) of the Schedule 13D is hereby supplemented as follows:
(a) See the responses set forth in Items 11 and 13 on page 2 for information
relating to beneficial ownership of Common Stock of
<PAGE>
Page 4 of 5 pages
the Company by the Reporting Person. Of the shares listed therein, 150,000
shares are subject to issuance upon exercise of options granted on March 21,
1995 to the Reporting Person under the Company's 1992 Stock Option Plan (as
amended). Such options are fully vested and currently exercisable at a per share
price of $2.66, the fair market value on the date of grant, and expire in March
2000.
(d) During January 1994, Magar Inc. borrowed funds from National
Westminster Bank USA (the "Bank") and, to date, has pledged 270,000 shares of
the Company's Common Stock owned by it to the Bank as security for the repayment
of such funds. In the event of default on the loan, the Bank shall have the
right to vote and/or dispose of such shares.
Item 7. Material to be filed as Exhibits.
The previous statements on Schedule 13D filed on February 23, 1995
on March 21, 1995 are attached hereto as exhibits.
<PAGE>
Page 5 of 5 pages
Signature
After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this Amendment is true,
complete and correct.
Dated: April 11, 1997
/s/ Herbert Moskowitz
---------------------
Herbert Moskowitz
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. __________)*
Life Medical Sciences, Inc.
- --------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, par value $.001 per share
- --------------------------------------------------------------------------------
(Title of Class of Securities)
53215M 101
------------------------------------------------------
(CUSIP Number)
Herbert Moskowitz, 616 Washington Court, Guilderland, New York 12084
(518) 456-1876, with a copy to Irwin M. Rosenthal, Esq.,
Rubin Baum Levin Constant & Friedman, 30 Rockefeller Plaza, New York, NY 10112
- --------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person Authorized to Receive Notices and
Communications)
February 23, 1995
- --------------------------------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(b)(3) or (4), check the following box |_|.
Check the following box if a fee is being paid with the statement |X|. (A fee is
not required only if the reporting person: (1) has a previous statement on file
reporting beneficial ownership of more than five percent of the class of
securities described in Item 1; and (2) has filed no amendment subsequent
thereto reporting beneficial ownership of five percent or less of such class.)
(See Rule 13d-7.)
Note: Six copies of this statement, including all exhibits, should be filed with
the Commission. See Rule 13d-1(a) for other parties to whom copies are to be
sent.
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
Page 1 of 9 pages
<PAGE>
SCHEDULE 13D
CUSIP NO. 53215M 101 Page 2 of 9 Pages
- --------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
Herbert Moskowitz
- --------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) |_|
(b) |X|
- --------------------------------------------------------------------------------
3 SEC USE ONLY
- --------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
PF
- --------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS
2(d) or 2(e) |_|
- --------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
United States
- --------------------------------------------------------------------------------
NUMBER OF 7 SOLE VOTING POWER 390,127 shares of Common Stock
SHARES (includes 147,430 shares of Common Stock
BENEFICIALLY issuable upon exercise of 49,110 Class A Warrants
OWNED BY and 49,110 Class B Warrants (including 49,110
EACH Class B Warrants underlying such Class A Warrants)
REPORTING --------------------------------------------------------
PERSON 8 SHARED VOTING POWER 857,500 shares of Common Stock
WITH which represents shares of Common Stock owned of
record by Magar Inc., in which the reporting
person is an officer, director and principal
stockholder.
--------------------------------------------------------
9 SOLE DISPOSITIVE POWER 390,127 shares of Common
Stock (includes 147,430 shares of Common Stock
issuable upon exercise of 49,110 Class A Warrants
and 49,110 Class B Warrants (including 49,110
Class B Warrants underlying such Class A Warrants)
--------------------------------------------------------
10 SHARED DISPOSITIVE POWER 857,500 shares of Common
which Stock represents shares of Common Stock
owned of record by Magar Inc., in which the
reporting person is an officer, director and
principal stockholder.
- --------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,247,627 shares of Common Stock (includes 147,430 shares of Common Stock
issuable upon exercise of 49,110 Class A Warrants and 49,110 Class B
Warrants including 49,110 Class B Warrants underlying such Class A
Warrants and 857,500 shares of Common Stock held of record by Magar Inc.)
- --------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* |_|
- --------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 28.0%
based upon 4,308,695 shares of Common Stock outstanding, which is the
total number of shares outstanding as at February 27, 1995, as indicated
by American Stock Transfer & Trust Company, the Company's transfer agent
together with 147,430 shares of Common Stock which the reporting person
has a right to acquire upon exercise of Class A Warrants and Class B
Warrants (including Class B Warrants underlying such Class A Warrants.)
- --------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
IN
- --------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7
(INCLUDING EXHIBITS) OF THE SCHEDULE AND THE SIGNATURE ATTESTATION.
<PAGE>
Page 3 of 9 pages
Herbert Moskowitz has been a principal stockholder, officer and
director of Life Medical Sciences, Inc. since its inception and has filed a
Statement on Schedule 13G dated February 10, 1993, as amended by Amendment No. 1
thereto dated May 19, 1994 and Amendment No. 2 thereto dated February 14, 1995,
reflecting his stock ownership in Life Medical Sciences, Inc. prior to the date
of the event requiring the filing of this Statement.
Item 1. Security and Issuer.
This statement relates to the Common Stock, par value $.001 per
share (the "Common Stock") of Life Medical Sciences, a Delaware corporation (the
"Company"). The address of the Company's principal executive office is 214
Carnegie Center, Princeton, New Jersey 08540
Item 2. Identity and Background.
(a) This statement is filed by Herbert Moskowitz (the "Reporting
Person").
(b) The principal business address of the Reporting Person is 616
Washington Court, Guilderland, New York 12084.
(c) The present principal occupation of the Reporting Person is
president and director of Magar Inc. and Chairman of the Board, Chief Executive
Officer and President of the Company. Magar Inc. is a private investment firm.
The Company is engaged
<PAGE>
Page 4 of 9 pages
in research and development of technologies for use in medical applications. The
Reporting Person is also an officer and/or director of various other public and
private companies engaged in research and development in the medical and
computer industries. The address of Magar Inc. is 616 Washington Court,
Guilderland, New York 12084. The address of the Company is 214 Carnegie Center,
Princeton, New Jersey 08540.
(d) During the last five years the Reporting Person has not been
convicted in a criminal proceeding (excluding traffic violations or similar
misdemeanors).
(e) During the last five years the Reporting Person has not been a
party to a civil proceeding of a judicial or administrative body of competent
jurisdiction as a result of which proceeding the Reporting Person was or is
subject to a judgment, decree or final order enjoining future violations of, or
prohibiting or mandating activities subject to, Federal or state securities laws
or finding any violation with respect to such laws.
(f) The Reporting Person is a citizen of the United States.
Item 3. Source and Amount of Funds or Other Consideration.
151,111 shares of Common Stock were issued by the Company in a
private transaction to the Reporting Person on February 23, 1995 in
consideration for the cancellation by the Reporting
<PAGE>
Page 5 of 9 pages
Person of indebtedness of the Company to the Reporting Person in the aggregate
amount of approximately $340,000 (including principal and accrued interest) (the
"Loan Conversion"). The cancelled indebtedness was originally provided from the
Reporting Person's personal funds. On February 23, 1995, 11,111 shares were sold
by the Reporting Person in a private transaction to an unrelated third party.
All securities owned of record by the Reporting Person were purchased by the
Reporting Person using his personal funds. The shares owned of record by Magar
Inc. were purchased using Magar Inc.'s working capital.
Item 4. Purpose of Transaction.
The Reporting Person's purpose in effecting the Loan Conversion was
to increase his equity interest in the Company while at the same time
strengthening the Company's financial position.
The Reporting Person intends to review his investment in the Company
on a continuing basis and, depending on various factors, including the Company's
business affairs and financial position, the price levels of the Company's
securities, conditions in the securities markets and general economic and
industry conditions, the Reporting Person will take such actions with respect to
his investment in the Company as he deems appropriate in light of the
circumstances existing from time to time. Such actions may include the
acquisition of additional securities
<PAGE>
Page 6 of 9 pages
through open market and privately negotiated transactions. The Reporting Person
may, and reserves the right to, sell some of all of his holdings in the open
market or in privately negotiated transactions to one or more purchasers. Except
as disclosed in this Item 4, the Reporting Person has no current plans or
proposals which relate to or would result in any of the events described in
Items (a) through (j) of the general instructions to Item 4 of Schedule 13D.
Item 5. Interest in Securities of the Issuer.
(a) See the responses set forth in Items 11 and 13 on page 2 for
information relating to beneficial ownership of Common Stock of the Company by
the Reporting Person. Each Class A Warrant currently entitles the holder to
purchase, until September 21, 1997, at an exercise price of $8.90, one share of
Common Stock and one Class B Warrant and each Class B Warrant currently entitles
the holder to purchase, until September 21, 1997, at an exercise price of
$13.36, one share of Common Stock.
(b) See the responses set forth in Items 7,8,9, and 10 on page 2 for
information relating to the Reporting Person's power to vote and dispose of the
shares of Common Stock.
Magar Inc. has its principal place of business at 616 Washington Court,
Guilderland, New York 12084. Magar Inc. is a private investment firm. The
officers and directors and principal stockholders of Magar Inc. include the
Reporting Person,
<PAGE>
Page 7 of 9 pages
Irwin M. Rosenthal, an attorney who is a partner at Rubin Baum Levin Constant &
Friedman, 30 Rockefeller Plaza, New York, NY 10112 (a law firm) and officer
and/or director of public and private companies, including the Company, and
Martin D. Fife who is the Chairman of the Board of Magar Inc. and officer and/or
director of public and private companies.
To the knowledge of the Reporting Person none of these persons has
been convicted in a criminal proceeding (excluding traffic violations or similar
misdemeanors) during the last five years and none of these persons, during the
last five years, has been a party to a civil proceeding of a judicial or
administrative body of competent jurisdiction as a result of which proceeding
was or is subject to a judgement, decree or final order enjoining future
violations of, or prohibiting mandatory activities subject to, Federal or state
securities laws or finding any violation with respect to such laws. Magar Inc.
is organized under the laws of Delaware. Each of the individuals referred to
above is a citizen of the United States.
(c) The Reporting Person has not effected any transactions during
the sixty days prior to the date hereof except for the Loan Conversion and the
sale of shares to an unrelated third party described in response to Item 3 on
pages 4 and 5, each of which was effected at a per share price of $2.25.
(d) No person other than the Reporting Person is known to have the
right to receive or the power to direct the receipt
<PAGE>
Page 8 of 9 pages
of dividends from or the proceeds from the sales of the shares of any securities
held of record by the Reporting Person.
Irwin M. Rosenthal, Herbert Moskowitz and Martin D. Fife each has a
right to receive certain percentages of dividends with respect to, and proceeds
from the sale of, shares of Common Stock of the Company held by Magar Inc. to
the extent such amounts constitute profits of Magar Inc.
During January 1994, Magar Inc. borrowed funds from National
Westminster Bank USA (the "Bank") and, to date, has pledged 450,000 of the
shares of the Company's Common Stock owned by it to the Bank as security for the
repayment of such funds. In the event of default on the loan, the Bank shall
have the right to vote and/or dispose of such shares.
(e) Not applicable.
Item 6. Contracts, Arrangements, Understanding or Relationship with Respect to
Securities of the Issuer.
See the response set forth in Item 5(d) on pages 7 and 8 for
information relating to division of profits.
Item 7. Material to be filed as Exhibits.
None
<PAGE>
Page 9 of 9 pages
Signature
After reasonable inquiry and to the best of my knowl edge and
belief, I certify that the information set forth in this statement is true,
complete and correct.
Dated: March 3, 1995 /s/ Herbert Moskowitz
------------------------------
Herbert Moskowitz
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
Life Medical Sciences, Inc.
- --------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, par value $.001 per share
- --------------------------------------------------------------------------------
(Title of Class of Securities)
53215M 101
- --------------------------------------------------------------------------------
(CUSIP Number)
Herbert Moskowitz, 616 Washington Court, Guilderland, New York 12084
(518) 456-1876, with a copy to Irwin M. Rosenthal, Esq.,
Rubin Baum Levin Constant & Friedman, 30 Rockefeller Plaza, New York, NY 10112
- --------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
March 21, 1995
- --------------------------------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(b)(3) or (4), check the following box |_|.
Check the following box if a fee is being paid with the statement |_|. (A fee is
not required only if the reporting person: (1) has a previous statement on file
reporting beneficial ownership of more than five percent of the class of
securities described in Item 1; and (2) has filed no amendment subsequent
thereto reporting beneficial ownership of five percent or less of such class.)
(See Rule 13d-7.)
Note: Six copies of this statement, including all exhibits, should be filed with
the Commission. See Rule 13d-1(a) for other parties to whom copies are to be
sent.
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
Page 1 of 4 pages
<PAGE>
SCHEDULE 13D
CUSIP NO. 53215M 101 Page 2 of 4 Pages
- --------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
Herbert Moskowitz
- --------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) |_|
(b) |x|
- --------------------------------------------------------------------------------
3 SEC USE ONLY
- --------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
N/A
- --------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) or 2(e) |_|
- --------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
United States
- --------------------------------------------------------------------------------
7 SOLE VOTING POWER 540,127 shares of Common Stock (includes
147,430 shares of Common Stock issuable upon exercise of
49,110 Class A Warrants and 49,110 Class B Warrants
(including 49,110 Class B Warrants underlying such Class A
Warrants) and 150,000 shares of Common Stock underlying
currently exercisable options).
------------------------------------------------------------------
8 SHARED VOTING POWER 857,500 shares of Common Stock which
NUMBER OF represents shares of Common Stock owned of record by Magar
SHARES Inc., in which the reporting person is an officer, director
BENEFICIALLY and principal stockholder.
OWNED BY ------------------------------------------------------------------
REPORTING 9 SOLE DISPOSITIVE POWER 540,127 shares of Common Stock
PERSON (includes 147,430 shares of Common Stock issuable upon
WITH exercise of 49,110 Class A Warrants and 49,110 Class B
Warrants (including 49,110 Class B Warrants underlying such
Class A Warrants) and 150,000 shares of Common Stock
underlying currently exercisable options)
-----------------------------------------------------------------
10 SHARED DISPOSITIVE POWER 857,500 shares of Common which
Stock represents shares of Common Stock owned of record by
Magar Inc., in which the reporting person is an officer,
director and principal stockholder.
- --------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,397,627 shares of Common Stock
- --------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* |_|
- --------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 30.3%
Based upon 4,308,695 shares of Common Stock outstanding, which is
the total number of shares outstanding as at February 27, 1995, as
indicated by American Stock Transfer & Trust Company, the
Company's transfer agent, together with 297,430 shares of Common
Stock underlying currently exercisable Class A Warrants and Class
B Warrants (including Class B Warrants underlying such Class A
Warrants) and underlying currently exercisable options.
- --------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
IN
- --------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7
(INCLUDING EXHIBITS) OF THE SCHEDULE AND THE SIGNATURE ATTESTATION.
<PAGE>
Page 3 of 4 pages
This Amendment No. 1 to the statement on Schedule 13D (as defined below)
supplements the statement on Schedule 13D relating to the event date of February
23, 1995 (the "Schedule 13D") by Herbert Moskowitz (the "Reporting Person"),
relating to the common stock, $.001 par value per share (the "Common Stock") of
Life Medical Sciences, Inc. (the "Company").
Item 5. Interest in Securities of the Issuer.
Item 5(a) of the Schedule 13D is hereby supplemented as follows:
(a) See the responses set forth in Items 11 and 13 on page 2 for
information relating to beneficial ownership of Common Stock of the Company by
the Reporting Person. Of the shares listed therein, 150,000 shares are subject
to issuance upon exercise of options granted on March 21, 1995 to the Reporting
Person under the Company's 1992 Stock Option Plan (as amended). Such options are
fully vested and currently exercisable at a per share price of $2.66, the fair
market value on the date of grant, and expire in March 2000.
<PAGE>
Page 4 of 4 pages
Signature
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this Amendment is true, complete and
correct.
Dated: April 26, 1995
/s/ Herbert Moskowitz
----------------------
Herbert Moskowitz
